Cardiome presents to FDA advisory body

Vancouver, BC – May 31, 2004 – Cardiovascular drug development company Cardiome Pharma says it will present information to the FDA Arthritis Drugs Advisory Committee on June 2.

The presentation will focus on oxypurinol as a treatment for allopurinol-intolerant gout patients. The advisory committee meeting has a broad mandate, which includes advising the FDA on gout clinical trial design, reviewing the Cardiome NDA application, and other items. Cardiome has been informed that there will not be a public vote by the committee on the Cardiome NDA application.